WithdrawnPhase 2ketamine

Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus

Sponsored by University of Alabama at Birmingham

NCT ID
NCT03115489
Start Date
2017-05-04
Est. Completion
2021-05-18

About This Study

The study will investigate the efficacy of the N-methyl-D-aspartate receptor antagonist ketamine as a first line agent in refractory status epilepticus versus traditional general anesthetic agents used for burst suppression that target the gamma-aminobutyric acid adrenergic receptors.

Conditions Studied

Refractory Epilepsy

Interventions

  • Traditional Treatment (Group T)
  • Ketamine Infusion (Group K)

Eligibility

Age:18 Years - 100 Years
Healthy Volunteers:Yes
View full eligibility criteria
Inclusion Criteria:

* Patients more than 18 years of age with a diagnosis of status epilepticus
* Considered for burst suppression therapy after failing 2 or 3 anti-epileptic medications

Exclusion Criteria:

* Post anoxic status epilepticus
* Pregnant women, as confirmed by urine, or blood human chorionic gonadotropin, ultrasound or physical exam
* Prisoners
* Age less than 18 years
* Allergy or sensitivity to the drug in question

Study Locations (1)

UAB Department of Anesthesiology and Perioperative Medicine
Birmingham, Alabama, United States

This trial is not recruiting

This study is currently not accepting new participants.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source